- Advanced Proteome Therapeutics Corporation (APC) announces its U.S. subsidiary, Advanced Proteome Therapeutics Inc. (APTI) is expanding operations with a new hire and additional lab space
- APTI has hired an organic chemist and acquired lab space for mammalian cell culture in the Boston University BioSquare facility
- The expansion is part of APTI’s plan to monetize its antibody-drug conjugate (ADC) platform through generation of marketable data with additional ADC constructs developed using its license ready conjugation technology
- Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of ADC through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads
- Advanced Proteome Therapeutics Corporation (APC) is down 2.44 per cent and is trading at $0.20 per share as of 11:42 p.m. ET
Advanced Proteome Therapeutics (APC) U.S. subsidiary, Advanced Proteome Therapeutics (APTI) is expanding operations with a new hire and additional lab space.
APTI has hired an organic chemist and acquired lab space for mammalian cell culture in the Boston University BioSquare facility.
The expansion is part of APTI’s plan to monetize its antibody-drug conjugate (ADC) platform through generation of marketable data with additional ADC constructs developed using its license ready conjugation technology.
This is while also developing new complementary platforms and seeking opportunities to develop wholly-owned therapeutic candidates.
Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of ADC through improved site-specific labelling, drug-antibody ratio control and enabling of combination payloads
The mammalian cell culture space will allow APTI to perform in vitro testing of ADCs in various cell-based models of cancer and healthy tissue.
The ability to do so enables rapid testing of platforms’ structure-activity relationship which greatly accelerates development timelines while also enabling preliminary testing of potential clinical candidate ADCs without outsourcing.
Dr. Saumyadip Nemu joins APTI from University of Arkansas where he completed his PhD in organic chemistry – medicinal chemistry.
Dr. Nemu expands APTI’s synthetic capabilities and will contribute to the more rapid generation of novel molecules.
His initial efforts are focused on the development of APTI’s linker technology which is designed to overcome adverse properties of the highly hydrophobic payloads used in ADCs.
The combination of the optimized linker and conjugation technology is expected to lead to superior ADCs, increase APTI’s attractiveness to potential collaborators and enhance the company’s ability to develop its own ADCs
Advanced Proteome Therapeutics Corporation (APC) is down 2.44 per cent and is trading at $0.20 per share as of 11:42 p.m. ET.
